Coya Therapeutics is planning to file a request with the U.S. Food and Drug Administration (FDA) to continue testing its investigational therapy COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS) in a Phase 2 clinical trial. The company is preparing a meeting with the regulatory agency…
Coya to meet with FDA about a Phase 2 trial of COYA 302 for ALS
Researchers have identified new genetic variants that might influence survival among sporadic amyotrophic lateral sclerosis (ALS) patients in Japan. Genetic analyses in more than 1,000 ALS patients uncovered that small changes in the FGF1, THSD7A, and LRP1 genes could affect patients’ prognosis. In patient-derived nerve cells, the identified variants led…
Decisions, decisions. When did making health decisions become so challenging for me? Well, it began after I was diagnosed with ALS. Scheduling annual health screens and medical treatments became complex decisions. Even purchasing a new pair of sneakers came with specific considerations. ALS has created a whole…
The axeALS Foundation is inviting people in the U.S. with amyotrophic lateral sclerosis (ALS) and demonstrable financial needs to apply for a grant to defray the cost of living with the progressive neurodegenerative disease. The application deadline is midnight Aug. 15. Institutions may apply as well, although…
While neurologists are frustrated with the treatments for amyotrophic lateral sclerosis (ALS) now on the market, they rapidly adopt new therapies that may delay disease progression for use among their patients with the neurodegenerative disorder. That’s according to Spherix Global Insights, a company providing market research and business…
ALS patients have many wants and needs to make life a little easier and more comfortable. We know we can’t get everything, but it doesn’t hurt to try. So here it goes. Our bodies were made to move; to be active rather than passive. Lack of movement leads to…
My brothers-in-law made me an incredibly kind offer while I was caregiving for my late husband, Jeff, as he was living with ALS. They offered to spend a long weekend in January caring for him at our home while I went on a getaway. They wanted to fly…
An earlier start to noninvasive ventilation (NIV) could help to improve respiratory function and prolong survival for people with amyotrophic lateral sclerosis (ALS), according to a small clinical trial in Spain. While many of the study’s findings failed to reach statistical significance, the researchers believe the data still support…
A couple weeks ago, a friend asked me, “What are you going to do for your birthday?” “We’ll just have a family dinner and play games,” I said. “That’s all I want.” When my husband, Todd, and I were married, we might have gone on a weekend getaway or out…
Mitsubishi Tanabe Pharma America (MTPA), which had been testing a once-daily regimen of its oral therapy Radicava ORS (edaravone) for amyotrophic lateral sclerosis (ALS), announced that it is discontinuing the Phase 3b trial and its extension study. That decision comes after an interim analysis by an independent…
Recent Posts
- New funding backs commercial readiness efforts for ALS therapy
- US lawmakers reintroduce bill to improve access to treatment for ALS
- An emotional dance performance mirrored my life with ALS
- Expanded access program for ALS drug MN-166 at 50% enrollment
- US clinical trials lack diverse representation of ALS patients